Advertisement

Kinins IV pp 55-59 | Cite as

T-Kinin and T-Kininogen — An Historical Overview

  • Lowell M. Greenbaum
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 198A)

Abstract

It is well known that bradykinin liberation of trypsin from mammalian plasmas reflects the levels of high (HMW) and low molecular weight (LMW) kininogens of the plasma. Consequently the addition of trypsin to plasma is classically used to measure the total kininogen content of plasma of all species1,2 by measuring the liberation of kinin. Kinin is generally measured by bioassay or by radioimmunoassay. It is important to understand that until 1983, when our laboratory on HPLC separation of kinins,3 investigators could not differentiate clearly between bradykinin and its analogs by the bioassay or radioimmunoassay techniques. Many assumptions were made particularly in terms that HMW and LMW kininogens were the important proteins liberating kinins in all species. One piece of evidence that seemed to indicate that a third kininogen other than LMW or HMW was present in some fluids was the isolation of leukokininogen from human ascites fluid by Roffman and Greenbaum.4 Leukokininogen was a poor substrate for kallikreins but did liberate a kinin (termed leukokinin by our laboratory) by either cathepsin D or trypsin. Hiroshi Okamoto joined our laboratory in 1982 and began a study on the relative concentration of leukokininogen compared to HMW and LMW kininogens in human, rabbit and rat plasmas. In order to obtain the total kininogen content, the classic concentration of 0.1 mg trypsin added to 1 ml of plasma was initially used.

Keywords

Acute Phase Protein Glass Powder Acid Protease Radioimmunoassay Technique Mammalian Plasma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    C. B. Diniz, and I. F. Carvalho, A micromethod for determination of bradykinin under several conditions, Ann. N.Y. Acad. Sci., 104: 77–89, (1963).PubMedCrossRefGoogle Scholar
  2. 2.
    Y. Uchida, and M. Katori, Differential assay method for high molecular weight and low molecular weight kininogens, Biochem. Pharmacol., 27: 1463–1470, (1978).Google Scholar
  3. 3.
    T. K. Narayanan, and L. M. Greenbaum, Detection and quantitation of fluorescamine labeled bradykinin, its analogues and metabolites using high-performance liquid chromatography, J. Chromatogr., 306: 109 – 116, (1984).PubMedCrossRefGoogle Scholar
  4. 4.
    S. Roffman, and L. M. Greenbaum, Properties of leukokininogen isolated from human neoplastic ascites, Biochem. Pharmacol., 28: 1043–1050, (1979).Google Scholar
  5. 5.
    H. Okamoto, and L. M. Greenbaum, Kininogen substrates for trypsin and cathepsin D in human, rabbit and rat plasma, Life Sci., 32: 2007–2013, (1983).PubMedCrossRefGoogle Scholar
  6. 6.
    L. M. Greenbaum, and K. S. Kim, The kinin-forming and kininase activities of rabbit polymorphonuclear leucocytes, Br. J. Pharm. and Chem., 29: 238–247, (1967).Google Scholar
  7. 7.
    H. Okamoto, and L. M. Greenbaum, Isolation and structure of T-kinin, Biochem. Biophys. Res. Commun., 112: 701–708, (1983).CrossRefGoogle Scholar
  8. 8.
    G. S. Bedi, J. Balwierczak, and N. Back, A new vasopeptide formed by the action of a Murphy-Sturm lymphosarcoma acid protease on rat plasma kininogen, Biochem. Biophys. Res. Commun., 112: 621 – 628, (1983).CrossRefGoogle Scholar
  9. 9.
    H. Okamoto, and L. M. Greenbaum, Purification of the rat plasma T- kininogen, (This volume).Google Scholar
  10. 10.
    R. Kageyama, N. Kitamura, H. Okhuba, and S. Nakanishi, Primary structures of the mRNAs encoding the rat precurosrs for bradykinin and T-kinin, J. Biol. Chem., 260: 12054–12059, (1985).Google Scholar
  11. 11.
    A. Barlas, H. Okamoto, and L. M. Greenbaum, T-kininogen - the major plasma kininogen in rat adjuvant arthritis, Biochem. Biophy. Res. Commun., 129: 280–286, (1985).CrossRefGoogle Scholar
  12. 12.
    A. Barlas, H. Okamoto, and L. M. Greenbaum, Increased plasma level of T-kininogen in rats treated with Freund’s adjuvant, (This volume).Google Scholar
  13. 13.
    V. Eisen, New aspects of kinin formation, Trends in Pharm. Sciences, 69: 190–191, (1985).Google Scholar
  14. 14.
    T. Cole, A. S. Inglis, C. M. Roxburgh, G. J, Hewlett, and G. Schreiber, Major acute phase 1-protein of the rat is homologous to bovine kininogen and contains the sequence for bradykinin: Its synthesis is regulated at the mRNA level, FEBS Lett., 182: 57–61, (1985).PubMedCrossRefGoogle Scholar
  15. 15.
    N. Itoh, F. Wakamori, H. Okamoto, and L. M. Greenbaum, T-kininogen as an acute phase reactant identical with thiol inhibitor in rat plasma, (This volume).Google Scholar
  16. 16.
    T. Sueyoshi, K. Enyoji, T. Shimada, H. Kato, S. Iwanaga, Y. Bando, E. Kominami, and N. Katunuma, A new function of kininogen as thiol-proteinase inhibitors: Inhibition of papain and cathepsins B,H and L by bovine, rat and human plasma kininogens, FEBS Lett., 182: 193–195, (1985).PubMedCrossRefGoogle Scholar
  17. 17.
    F. Esnard, and F. Gauthier, An acute phase reactant identical with 1-acute phase globulin, J. B. Chem., 258: 12443–12447, (1983).Google Scholar
  18. 18.
    W. Muller-Esterl, H. Fritz, W. Machleidt, A. Ritonja, J. Brzin, M. Kotnik, V. Turk, J. Kellarmann, and F. Lottspeich, Human plasma kininogens are identical with 1-cystein proteinase inhibitors, FEBS Lett., 182: 310–314, (1985).PubMedCrossRefGoogle Scholar
  19. 19.
    H. Okamoto, and L. M. Greenbaum, Pharmacological properties of T-kinin (Isoleucyl-Seryl-Bradykinin) from rat plasma, Biochem. Pharmacol., 32: 2637–2638, (1983).Google Scholar
  20. 20.
    A. Barlas, K. Sugio, and L. M. Greenbaum, Release of T-kinin and brady kinin in carrageenin induced inflammation in the rat, FEBS Lett., 190: 268–270, (1980).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Lowell M. Greenbaum
    • 1
  1. 1.Department of PharmacologyMedical College of GeorgiaAugustaUSA

Personalised recommendations